Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
TAK or STVN: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 11'th Mar 2024
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attracti
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production
01:07am, Tuesday, 27'th Feb 2024
Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.
US FDA approves Takeda's therapy for allergic inflammation in esophagus
08:13am, Monday, 12'th Feb 2024
Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the conditio
Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
02:15pm, Friday, 02'nd Feb 2024
Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
3 Stocks to Buy to Benefit From the Booming Sleep Industry
02:30pm, Tuesday, 23'rd Jan 2024
Google “How important is sleep?” and you get three billion results.
One Ultra-Cheap High-Yield Dividend Stock to Buy
05:35am, Friday, 22'nd Dec 2023
Takeda Pharmaceutical is one of the top pharma companies in the world. It has a broad mix of products in its portfolio, which can provide investors with some stability.
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
11:17am, Thursday, 07'th Dec 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
11:16am, Friday, 17'th Nov 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
US FDA approves Takeda's blood disorder therapy
03:08pm, Thursday, 09'th Nov 2023
The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients.
Takeda says FDA approves its treatment for colorectal cancer
07:22pm, Wednesday, 08'th Nov 2023
Pharmaceutical company Takeda 4502, +0.29% said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.
TAK vs. STVN: Which Stock Is the Better Value Option?
12:47pm, Friday, 27'th Oct 2023
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks presents investo
Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript
02:02am, Friday, 27'th Oct 2023
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber -
Japan's Takeda slashes full-year profit forecast on drug pipeline impairments
02:06am, Thursday, 26'th Oct 2023
Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its development pipeline and the loss of patent protecti
Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
02:43pm, Tuesday, 24'th Oct 2023
High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to meet key endpoints, thus impacting the company's FY23
Takeda trial for Crohn's Perianal Fistulas treatment misses primary endpoint
08:12pm, Tuesday, 17'th Oct 2023
Takeda 4502, -0.33% said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
